(Total Views: 564)
Posted On: 05/13/2021 2:44:41 PM
Post# of 72444
There remains an awful lot of groping for therapeutics. Room indeed for even a moderately effective COVID-19 therapeutic to seize the market. Enter Brilacidin.
Poster's Note: In the kingdom of the blind, the one eyed man is king. Brilacidin , which has shown promise against SARS-CoV-2 (and other viruses), in pre-clinical studies and has proven successful in multiple clinical trials as an antibacterial and immunomodulator is poised for its coronation .
Brazilian Covid variant in Illinois leads to a pause in shipments of Lilly’s mAb combo
https://endpts.com/brazilian-covid-variant-in...mab-combo/
Excerpt: The US is pausing shipments of Eli Lilly’s Covid-19 treatment combo (bamlanivimab and etesevimab) to Illinois because of the increased frequency of the coronavirus variant that originated in Brazil, known also as the P.1 variant.
The FDA is now recommending that health care providers in Illinois instead use Regeneron’s monoclonal antibody combo therapy of casirivimab with imdevimab, which it said is likely to retain activity against the P.1 variant, until further notice.
Poster's Note: In the kingdom of the blind, the one eyed man is king. Brilacidin , which has shown promise against SARS-CoV-2 (and other viruses), in pre-clinical studies and has proven successful in multiple clinical trials as an antibacterial and immunomodulator is poised for its coronation .
Brazilian Covid variant in Illinois leads to a pause in shipments of Lilly’s mAb combo
https://endpts.com/brazilian-covid-variant-in...mab-combo/
Excerpt: The US is pausing shipments of Eli Lilly’s Covid-19 treatment combo (bamlanivimab and etesevimab) to Illinois because of the increased frequency of the coronavirus variant that originated in Brazil, known also as the P.1 variant.
The FDA is now recommending that health care providers in Illinois instead use Regeneron’s monoclonal antibody combo therapy of casirivimab with imdevimab, which it said is likely to retain activity against the P.1 variant, until further notice.
(5)
(0)
